These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8858938)

  • 1. Preferential vulnerability of nucleus accumbens dopamine binding sites to low-level lead exposure: time course of effects and interactions with chronic dopamine agonist treatments.
    Pokora MJ; Richfield EK; Cory-Slechta DA
    J Neurochem; 1996 Oct; 67(4):1540-50. PubMed ID: 8858938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course and regional basis of Pb-induced changes in MK-801 binding: reversal by chronic treatment with the dopamine agonist apomorphine but not the D1 agonist SKF-82958.
    Cory-Slechta DA; McCoy L; Richfield EK
    J Neurochem; 1997 May; 68(5):2012-23. PubMed ID: 9109527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional decreases in alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) and 6-[3H]cyano-7-nitroquinoxaline-2,3-dione ([3H]CNQX) binding in response to chronic low-level lead exposure: reversal versus potentiation by chronic dopamine agonist treatment.
    McCoy L; Richfield EK; Cory-Slechta DA
    J Neurochem; 1997 Dec; 69(6):2466-76. PubMed ID: 9375679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective modifications in the nucleus accumbens of dopamine synaptic transmission in rats exposed to chronic stress.
    Scheggi S; Leggio B; Masi F; Grappi S; Gambarana C; Nanni G; Rauggi R; De Montis MG
    J Neurochem; 2002 Nov; 83(4):895-903. PubMed ID: 12421362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration.
    Claye LH; Akunne HC; Davis MD; DeMattos S; Soliman KF
    Mol Neurobiol; 1995; 11(1-3):55-66. PubMed ID: 8561968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat.
    Kimmel HL; Joyce AR; Carroll FI; Kuhar MJ
    J Pharmacol Exp Ther; 2001 Jul; 298(1):129-40. PubMed ID: 11408534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. There is a limited critical period for dopamine's effects on D1 receptor expression in the developing rat neostriatum.
    Thomas WS; Neal-Beliveau BS; Joyce JN
    Brain Res Dev Brain Res; 1998 Nov; 111(1):99-106. PubMed ID: 9804909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basolateral amygdala modulation of the nucleus accumbens dopamine response to stress: role of the medial prefrontal cortex.
    Stevenson CW; Gratton A
    Eur J Neurosci; 2003 Mar; 17(6):1287-95. PubMed ID: 12670317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of postnatal lead-induced changes in dopamine receptors and their relationship to changes in dopamine sensitivity.
    Widzowski DV; Finkelstein JN; Pokora MJ; Cory-Slechta DA
    Neurotoxicology; 1994; 15(4):853-65. PubMed ID: 7715856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of increased dopamine receptor signaling in food-restricted rats.
    Carr KD; Tsimberg Y; Berman Y; Yamamoto N
    Neuroscience; 2003; 119(4):1157-67. PubMed ID: 12831870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead-induced decrements in waiting behavior: involvement of D2-like dopamine receptors.
    Brockel BJ; Cory-Slechta DA
    Pharmacol Biochem Behav; 1999 Jul; 63(3):423-34. PubMed ID: 10418784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of repeated injections of cocaine on catecholamine receptor binding sites, dopamine transporter binding sites and behavior in rhesus monkey.
    Farfel GM; Kleven MS; Woolverton WL; Seiden LS; Perry BD
    Brain Res; 1992 Apr; 578(1-2):235-43. PubMed ID: 1380862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
    Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs.
    Hooks MS; Juncos JL; Justice JB; Meiergerd SM; Povlock SL; Schenk JO; Kalivas PW
    J Neurosci; 1994 Oct; 14(10):6144-52. PubMed ID: 7931568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of basal and D-1 dopamine receptor agonist-stimulated neuropeptide gene expression in caudate-putamen and nucleus accumbens of ad libitum fed and food-restricted rats.
    Haberny SL; Carr KD
    Brain Res Mol Brain Res; 2005 Nov; 141(2):121-7. PubMed ID: 16257473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in mesocorticolimbic dopamine and D1/D2 receptor levels after low level lead exposure: a time course study.
    Gedeon Y; Ramesh GT; Wellman PJ; Jadhav AL
    Toxicol Lett; 2001 Sep; 123(2-3):217-26. PubMed ID: 11641049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead-induced changes in dopamine D1 sensitivity: modulation by drug discrimination training.
    Cory-Slechta DA; Pokora MJ; Fox RA; O'Mara DJ
    Neurotoxicology; 1996; 17(2):445-57. PubMed ID: 8856740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors.
    Izenwasser S; Acri JB; Kunko PM; Shippenberg T
    Synapse; 1998 Nov; 30(3):275-83. PubMed ID: 9776131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.